Astrazeneca Pharma India Ltd

Astrazeneca Phar Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astrazeneca Pharma India Ltd

₹ 5,285 0.75%
24 Apr - close price
astrazenecaindia.com BSE: 506820 NSE : ASTRAZEN
About

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Key Points

Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]

Website BSE NSE
  • Market Cap ₹ 13,212 Cr.
  • Current Price ₹ 5,285
  • High / Low ₹ 7,221 / 3,125
  • Stock P/E 82.8
  • Book Value ₹ 262
  • Dividend Yield 0.30 %
  • ROCE 30.9 %
  • ROE 23.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 37.3% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 28.7%

Cons

  • Stock is trading at 20.2 times its book value
  • The company has delivered a poor sales growth of 11.9% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
200 210 175 198 201 232 232 236 250 285 295 311 306
170 170 160 180 186 194 204 195 213 225 228 258 291
Operating Profit 31 40 16 18 15 38 28 41 37 60 67 53 15
OPM % 15% 19% 9% 9% 7% 16% 12% 17% 15% 21% 23% 17% 5%
3 3 3 3 5 4 4 7 7 -32 8 25 10
Interest 0 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 5 6 5 4 4 4 5 3 4 4 4 4 4
Profit before tax 28 37 14 16 16 37 27 44 39 23 71 73 20
Tax % 26% 26% 24% 26% 30% 24% 26% 26% 26% 26% 25% 29% 22%
21 27 10 12 11 28 20 33 29 17 54 52 16
EPS in Rs 8.42 10.91 4.10 4.78 4.57 11.19 8.06 13.02 11.72 6.91 21.54 20.95 6.32
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
531 390 474 517 564 544 571 728 832 814 806 1,003 1,197
501 459 487 528 547 506 525 657 711 678 719 838 1,002
Operating Profit 30 -68 -13 -11 16 37 46 71 121 135 86 165 195
OPM % 6% -18% -3% -2% 3% 7% 8% 10% 15% 17% 11% 16% 16%
6 10 23 6 7 14 12 16 13 13 15 -14 10
Interest 0 0 0 0 0 0 0 0 1 1 1 1 1
Depreciation 7 12 10 15 17 16 15 15 19 20 17 16 15
Profit before tax 29 -70 0 -21 6 36 44 73 114 127 83 134 188
Tax % 32% -27% 0% 9% 44% 41% 25% 37% 27% 26% 26%
20 -90 -1 -21 5 20 26 54 72 93 62 99 139
EPS in Rs 7.90 -35.81 -0.20 -8.34 2.10 8.02 10.36 21.78 28.88 37.32 24.64 39.72 55.72
Dividend Payout % 44% 0% 0% 0% 0% 0% 0% 0% 3% 5% 41% 40%
Compounded Sales Growth
10 Years: 10%
5 Years: 12%
3 Years: 6%
TTM: 26%
Compounded Profit Growth
10 Years: 13%
5 Years: 37%
3 Years: 21%
TTM: 45%
Stock Price CAGR
10 Years: 17%
5 Years: 18%
3 Years: 7%
1 Year: 67%
Return on Equity
10 Years: 14%
5 Years: 20%
3 Years: 19%
Last Year: 23%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 5 5 5 5 5 5 5 5 5 5 5 5 5
Reserves 184 95 167 146 151 218 242 296 359 451 506 584 650
0 0 0 0 0 0 0 0 12 12 9 7 5
156 206 244 261 247 193 214 261 330 306 337 389 441
Total Liabilities 345 306 416 412 403 415 461 562 706 775 857 985 1,102
32 25 94 101 97 87 75 75 72 81 74 69 65
CWIP 58 74 9 12 6 5 4 7 24 4 2 1 1
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
255 208 312 298 299 324 382 480 611 690 780 915 1,036
Total Assets 345 306 416 412 403 415 461 562 706 775 857 985 1,102

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
39 -6 -1 -46 57 38 9 55 87 105 101 58
-34 -16 -15 -19 -4 0 -9 4 -171 173 5 18
-29 -10 86 0 -1 0 0 0 -6 -9 -9 -24
Net Cash Flow -24 -32 71 -64 53 38 -1 59 -90 269 96 52

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 22 26 41 30 54 29 35 40 37 38 39 39
Inventory Days 153 202 210 157 141 121 229 186 197 198 164 193
Days Payable 43 214 241 203 174 184 257 266 251 221 223 231
Cash Conversion Cycle 133 14 10 -16 21 -34 7 -39 -17 15 -20 1
Working Capital Days -9 -56 -45 -15 -28 -36 -8 -14 -15 -15 -33 -17
ROCE % 15% -53% -12% -13% 4% 15% 19% 27% 34% 30% 16% 31%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.42% 2.40% 2.38% 2.38% 2.48% 2.49% 2.61% 2.70% 2.68% 2.69% 2.66% 2.73%
1.02% 1.05% 1.14% 1.19% 1.30% 1.32% 1.42% 1.41% 1.91% 2.42% 2.76% 3.77%
21.56% 21.55% 21.48% 21.43% 21.22% 21.19% 20.97% 20.88% 20.40% 19.89% 19.57% 18.50%
No. of Shareholders 68,07766,44462,18357,76053,98049,08545,61942,14638,94632,38029,03229,418

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls